Stoke Therapeutics, Inc. (STOK)
STOK Stock Price Chart
Explore Stoke Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze STOK price movements and trends.
STOK Company Profile
Discover essential business fundamentals and corporate details for Stoke Therapeutics, Inc. (STOK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jun 2019
Employees
128.00
CEO
Ian F. Smith
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
STOK Financial Timeline
Browse a chronological timeline of Stoke Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.56.
Earnings released on 12 Aug 2025
EPS came in at -$0.40 surpassing the estimated -$0.57 by +29.82%, while revenue for the quarter reached $13.82M , beating expectations by +157.99%.
Earnings released on 13 May 2025
EPS came in at $1.90 surpassing the estimated -$0.37 by +613.51%, while revenue for the quarter reached $158.57M , beating expectations by +403.19%.
Earnings released on 18 Mar 2025
EPS came in at -$0.18 surpassing the estimated -$0.51 by +64.71%, while revenue for the quarter reached $22.61M , beating expectations by +485.85%.
Earnings released on 5 Nov 2024
EPS came in at -$0.47 surpassing the estimated -$0.52 by +9.62%, while revenue for the quarter reached $4.89M , beating expectations by +16.52%.
Earnings released on 7 Aug 2024
EPS came in at -$0.46 surpassing the estimated -$0.57 by +19.30%, while revenue for the quarter reached $4.83M , beating expectations by +48.19%.
Earnings released on 6 May 2024
EPS came in at -$0.57 surpassing the estimated -$0.60 by +5.00%, while revenue for the quarter reached $4.22M , beating expectations by +31.34%.
Earnings released on 25 Mar 2024
EPS came in at -$0.60 surpassing the estimated -$0.62 by +3.23%, while revenue for the quarter reached $2.80M , missing expectations by -13.78%.
Earnings released on 7 Nov 2023
EPS came in at -$0.55 surpassing the estimated -$0.65 by +15.38%, while revenue for the quarter reached $3.31M , beating expectations by +1.78%.
Earnings released on 7 Aug 2023
EPS came in at -$0.69 falling short of the estimated -$0.65 by -6.15%, while revenue for the quarter reached -$2.48M , missing expectations by -178.26%.
Earnings released on 4 May 2023
EPS came in at -$0.53 surpassing the estimated -$0.70 by +24.29%, while revenue for the quarter reached $5.15M , beating expectations by +71.73%.
Earnings released on 6 Mar 2023
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%, while revenue for the quarter reached $3.27M , beating expectations by +14.19%.
Earnings released on 14 Nov 2022
EPS came in at -$0.66 surpassing the estimated -$0.69 by +4.35%, while revenue for the quarter reached $2.91M , beating expectations by +6.71%.
Earnings released on 8 Aug 2022
EPS came in at -$0.63 surpassing the estimated -$0.70 by +10.00%, while revenue for the quarter reached $3.23M , beating expectations by +22.36%.
Earnings released on 10 May 2022
EPS came in at -$0.66 falling short of the estimated $0.61 by -208.20%, while revenue for the quarter reached $3.00M , missing expectations by -94.00%.
Earnings released on 10 Mar 2022
EPS came in at -$0.66 falling short of the estimated -$0.62 by -6.45%.
Earnings released on 8 Nov 2021
EPS came in at -$0.61 falling short of the estimated -$0.58 by -5.17%.
Earnings released on 10 Aug 2021
EPS came in at -$0.60 falling short of the estimated -$0.49 by -22.45%.
Earnings released on 10 May 2021
EPS came in at -$0.46 falling short of the estimated -$0.44 by -4.55%.
Earnings released on 9 Mar 2021
EPS came in at -$0.42 surpassing the estimated -$0.43 by +2.33%.
Earnings released on 12 Nov 2020
EPS came in at -$0.41 surpassing the estimated -$0.42 by +2.38%.
STOK Stock Performance
Access detailed STOK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.